Halozyme Therapeutics (HALO) News Today → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free HALO Stock Alerts $44.71 -0.68 (-1.50%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 5:21 PM | marketbeat.comWafra Inc. Acquires 23,811 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Wafra Inc. grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 79.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 53,877 shares of the biopharmaceutical company's stock after purchasing an addiMay 17 at 4:21 AM | marketbeat.comInternational Assets Investment Management LLC Buys New Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)International Assets Investment Management LLC bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 27,868 shares of the biopharmaceutical company's stock, valued at approximateMay 16 at 7:28 PM | finance.yahoo.comHalozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS RatingMay 16 at 8:59 AM | marketbeat.comBoston Partners Purchases 468,977 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Boston Partners increased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 562.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 552,392 shares of the biopharmaceutical company'sMay 14, 2024 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Hits New 52-Week High at $45.15Halozyme Therapeutics (NASDAQ:HALO) Hits New 1-Year High at $45.15May 13, 2024 | marketbeat.comSwiss National Bank Decreases Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Swiss National Bank decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 10.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 260,000 shares of the biopharmaceutical company'sMay 11, 2024 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Position Raised by Mesirow Institutional Investment Management Inc.Mesirow Institutional Investment Management Inc. raised its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 19.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 453,827 shareMay 10, 2024 | finance.yahoo.comBiotech Stocks To Watch: Halozyme Actionable Now After Earnings-Fueled BreakoutMay 10, 2024 | americanbankingnews.comHalozyme Therapeutics (NASDAQ:HALO) Price Target Cut to $71.00May 10, 2024 | marketbeat.comCwm LLC Cuts Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Cwm LLC decreased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 97.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,113 shares of the biopharMay 9, 2024 | investorplace.comThe 3 Best Biotech Stocks to Buy in May 2024May 9, 2024 | seekingalpha.comHalozyme Therapeutics, Inc. (HALO) Q1 2024 Earnings Call TranscriptMay 8, 2024 | washingtonpost.comThe Trade Desk: Q1 Earnings SnapshotMay 8, 2024 | finance.yahoo.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call TranscriptMay 8, 2024 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Trading Up 5.9%Halozyme Therapeutics (NASDAQ:HALO) Shares Up 5.9%May 8, 2024 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) PT Lowered to $71.00 at JMP SecuritiesJMP Securities cut their target price on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a "market outperform" rating for the company in a research note on Wednesday.May 8, 2024 | finance.yahoo.comQ1 2024 Halozyme Therapeutics Inc Earnings CallMay 8, 2024 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Updates FY 2024 Earnings GuidanceHalozyme Therapeutics (NASDAQ:HALO) updated its FY 2024 earnings guidance. The company provided EPS guidance of 3.550-3.900 for the period, compared to the consensus estimate of 3.680. The company also issued revenue guidance of $915.0 millionillion-$985.0 millionillion, compared to the consensus estimate of $951.5 millionillion.May 8, 2024 | prnewswire.comHalozyme to Participate in Upcoming Investor ConferencesMay 8, 2024 | finance.yahoo.comHalozyme Therapeutics Inc (HALO) (Q1 2024) Earnings Call Transcript Highlights: Robust Growth ...May 7, 2024 | investorplace.comHALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024May 7, 2024 | finance.yahoo.comHalozyme Therapeutics: Q1 Earnings SnapshotMay 7, 2024 | finance.yahoo.comHalozyme Therapeutics Q1 2024 Earnings: Misses EPS Estimates but Shows Revenue GrowthMay 7, 2024 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Issues FY24 Earnings GuidanceHalozyme Therapeutics (NASDAQ:HALO) updated its FY24 earnings guidance. The company provided EPS guidance of $3.55-3.90 for the period, compared to the consensus estimate of $3.52. The company also issued revenue guidance of $915-985 millionillion, compared to the consensus estimate of $954.43 millionillion.May 7, 2024 | seekingalpha.comHalozyme Therapeutics, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 7, 2024 | prnewswire.comHALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTSMay 7, 2024 | marketbeat.comLSV Asset Management Invests $17.09 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)LSV Asset Management purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 462,400 shares of the biopharmaMay 5, 2024 | marketbeat.comRussell Investments Group Ltd. Trims Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Russell Investments Group Ltd. lowered its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 14.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 359,706 shares of the biopharmaceutical compMay 3, 2024 | finance.yahoo.comHow Novo-Catalent Deal Affects Halozyme (HALO)?April 30, 2024 | markets.businessinsider.comBuy Rating Affirmed for Halozyme on Strong Technology Prospects and Strategic PartnershipsApril 30, 2024 | marketbeat.comHalozyme Therapeutics (HALO) Set to Announce Earnings on TuesdayHalozyme Therapeutics (NASDAQ:HALO) will be releasing earnings after the market closes on Tuesday, May 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=587909)April 30, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Halozyme Therapeutics (NASDAQ:HALO)HC Wainwright reissued a "buy" rating and set a $50.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday.April 29, 2024 | msn.comSarepta Therapeutics Stock Shows Improved Technical StrengthApril 29, 2024 | msn.comHuonslab applies for clinical trial of hyaluronidase drugApril 25, 2024 | prnewswire.comMahesh Krishnan Elected to Halozyme's Board of DirectorsApril 25, 2024 | markets.businessinsider.comCrossject reports audited financial results for 2023April 25, 2024 | marketbeat.comHandelsbanken Fonder AB Purchases 222,200 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Handelsbanken Fonder AB increased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 930.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 246,069 shares of the biopharmaceutical company's stock after buying an additional 222,200 shaApril 25, 2024 | investorplace.com3 Biotech Stocks That Could Be Multibaggers in the Making: April EditionApril 24, 2024 | marketbeat.comZacks Research Comments on Halozyme Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:HALO)Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Analysts at Zacks Research boosted their FY2026 earnings per share (EPS) estimates for shares of Halozyme Therapeutics in a research report issued to clients and investors on Monday, April 22nd. Zacks Research analyst A. Chakraborty now anApril 23, 2024 | finance.yahoo.comHalozyme to Report First Quarter 2024 Financial and Operating ResultsApril 23, 2024 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) to Post Q3 2025 Earnings of $1.01 Per Share, Zacks Research ForecastsHalozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Zacks Research upped their Q3 2025 earnings per share estimates for shares of Halozyme Therapeutics in a research note issued to investors on Monday, April 22nd. Zacks Research analyst A. Chakraborty now expects that the biopharmaceuticalApril 23, 2024 | marketbeat.comFederated Hermes Inc. Buys 292,926 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Federated Hermes Inc. grew its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 176.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 459,369 shares of the biopharmaceuticaApril 22, 2024 | marketbeat.comLouisiana State Employees Retirement System Purchases New Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Louisiana State Employees Retirement System acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 37,100 shares of the biopharmaceutical company's stock, vApril 21, 2024 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Holdings Raised by Kornitzer Capital Management Inc. KSKornitzer Capital Management Inc. KS grew its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 5.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 474,734 shares of the biophaApril 19, 2024 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Knights of Columbus Asset Advisors LLCKnights of Columbus Asset Advisors LLC raised its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 99.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 185,845 sharApril 19, 2024 | insidertrades.comMichael J. Labarre Sells 10,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) StockApril 19, 2024 | investing.comHalozyme Therapeutics CTO sells $768,390 in stockApril 18, 2024 | insidertrades.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre Sells 10,000 SharesApril 17, 2024 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Sells $384,900.00 in StockHalozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $38.49, for a total transaction of $384,900.00. Following the transaction, the senior vice president now directly owns 168,176 shares in the company, valued at $6,473,094.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.April 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Halozyme on OCREVUS SC Prospects and Enhanze Technology Potential Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget Bitcoin: This $8 Stock Is the Next Big Thing (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December. Get the name of the stock here >>> HALO Media Mentions By Week HALO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HALO News Sentiment▼1.180.42▲Average Medical News Sentiment HALO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HALO Articles This Week▼65▲HALO Articles Average Week Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: EXEL News Today RGEN News Today RLAY News Today NVAX News Today ALLO News Today ADPT News Today FATE News Today KOD News Today NBIX News Today IBRX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HALO) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBill Gates is all about this tiny $2 stockTimothy SykesElon’s New Device is About to Shock the WorldInvestorPlaceForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingBuy this small stock before coming AI Tidal WaveChaikin AnalyticsShocking $16T Elon Musk Crypto LeakCrypto 101 Media[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
